Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | RPA1 | P27694 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.43 |
| ▸ | BCL2 | P10415 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | MARS1 | P56192 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17013588 | 0.87 | P2RY1 (0.48) | ALDH1A1KMT2AMEN1MAPTGAA | |
| SCHEMBL12361519 | 0.81 | PTGS1 (0.52) | ALDH1A1 | |
| SCHEMBL5162940 | 0.78 | MDM2 (0.51) | ALDH1A1RPA1KMT2AL3MBTL1MEN1 | |
| SCHEMBL2320824 | 0.77 | ALDH1A1 (0.59) | ALDH1A1RPA1KMT2AL3MBTL1PPP1CA | |
| SCHEMBL16597799 | 0.77 | KMT2A (0.55) | ALDH1A1KMT2AMEN1MAPTMDM2 | |
| SCHEMBL4125657 | 0.74 | MAPT (0.53) | ALDH1A1KMT2AMEN1MAPTGAA | |
| SCHEMBL3975817 | 0.74 | ALDH1A1 (0.72) | ALDH1A1RPA1KMT2AL3MBTL1MEN1 | |
| SCHEMBL2317433 | 0.73 | MDM2 (0.64) | ALDH1A1RPA1KMT2AMEN1MAPT | |
| SCHEMBL17013177 | 0.72 | KMT2A (0.50) | ALDH1A1KMT2AMEN1MAPTGAA | |
| SCHEMBL22493515 | 0.71 | SCN9A (0.54) | KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2933248-B1 | NOVEL RENIN INHIBITOR | MITSUBISHI TANABE PHARMA CORP (JP) | 2018-01-31 | — | — | EP | disclosed |
| US-9556159-B2 | Renin inhibitor | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-01-31 | — | — | US | disclosed |
| EP-2933248-A1 | NOVEL RENIN INHIBITOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2015-10-21 | — | — | EP | disclosed |
| US-20150232459-A1 | NOVEL RENIN INHIBITOR | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232459-A1 | NOVEL RENIN INHIBITOR | REN, AGTR1, ACE | ALDH1A1 2192/4885RPA1 3249/4885KMT2A 1998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.